Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s stock price traded up 8% during trading on Monday . The company traded as high as $10.25 and last traded at $10.49. 50,125 shares were traded during mid-day trading, a decline of 92% from the average session volume of 591,811 shares. The stock had previously closed at $9.71.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on the stock. Wall Street Zen lowered shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. HC Wainwright lowered their price objective on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Wedbush restated an "outperform" rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research note on Friday, May 23rd. Wells Fargo & Company upgraded shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price objective on the stock in a research note on Friday, May 23rd. Finally, Stifel Nicolaus set a $48.00 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $31.86.
View Our Latest Research Report on BCAX
Bicara Therapeutics Price Performance
The firm's 50 day moving average price is $11.03 and its 200-day moving average price is $12.46.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.28). Research analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.
Institutional Investors Weigh In On Bicara Therapeutics
Institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new stake in Bicara Therapeutics during the fourth quarter worth $25,000. BNP Paribas Financial Markets acquired a new stake in Bicara Therapeutics during the fourth quarter worth $32,000. Legal & General Group Plc acquired a new stake in Bicara Therapeutics during the fourth quarter worth $33,000. Summit Investment Advisors Inc. acquired a new stake in Bicara Therapeutics during the fourth quarter worth $35,000. Finally, CWM LLC acquired a new stake in Bicara Therapeutics during the first quarter worth $29,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Featured Articles
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
